RT Journal Article
SR Electronic
T1 Development and validation of blood-based prognostic biomarkers for severity of COVID disease outcome using EpiSwitch 3D genomic regulatory immuno-genetic profiling
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.21.21259145
DO 10.1101/2021.06.21.21259145
A1 Ewan Hunter
A1 Christina Koutsothanasi
A1 Adam Wilson
A1 Francisco C. Santos
A1 Matthew Salter
A1 Jurjen W. Westra
A1 Ryan Powell
A1 Ann Dring
A1 Paulina Brajer
A1 Benedict Egan
A1 Matthew Parnall
A1 Catriona Williams
A1 Aemilia Katzinski
A1 Thomas Lavin
A1 Aroul Ramadass
A1 William Messer
A1 Amanda Brunton
A1 Zoe Lyski
A1 Rama Vancheeswaran
A1 Andrew Barlow
A1 Dmitri Pchejetski
A1 Peter A. Robbins
A1 Jane Mellor
A1 Alexandre Akoulitchev
YR 2021
UL http://medrxiv.org/content/early/2021/06/28/2021.06.21.21259145.abstract
AB The COVID-19 pandemic has raised several global public health challenges to which the international medical community have responded. Diagnostic testing and the development of vaccines against the SARS-CoV-2 virus have made remarkable progress to date. As the population is now faced with the complex lifestyle and medical decisions that come with living in a pandemic, a forward-looking understanding of how a COVID-19 diagnosis may affect the health of an individual represents a pressing need. Previously we used whole genome microarray to identify 200 3D genomic marker leads that could predict mild or severe COVID-19 disease outcomes from blood samples in a multinational cohort of COVID-19 patients. Here, we focus on the development and validation of a qPCR assay to accurately predict severe COVID-19 disease requiring intensive care unit (ICU) support and/or mechanical ventilation. From 200 original biomarker leads we established a classification model containing six markers. The markers were qualified and validated on 38 COVID-19 patients from an independent cohort. Overall, the six-marker model obtained a positive predictive value of 93% and balanced accuracy of 88% across 116 patients for the prognosis of COVID-19 severity requiring ICU care/ventilation support. The six-marker signature identifies individuals at the highest risk of developing severe complications in COVID-19 with high predictive accuracy and can assist in patient prognosis and clinical management decisions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by Oxford BioDynamics.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All clinical samples were provided by commercial suppliers Boca Biolistics LLC (FL, USA) and Reprocell USA Inc. (MD, USA), on the basis of protocol CRSPTL-00049 approved Dec 19, 2019 by Research Ethics Committee, Santo Domingo, Distrito Nacional, Dominican Republic; and Extra Institutional BB-ID-061 protocol for clinical sample collection approved by Institutional Committee of Ethics in Research, September 1, 2020, to the standards of National Health Institute of Health, pursuant to the Investigational Regional priorities and data reliability. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are openly available and can be found on the Github repo: https://github.com/oxfordBiodynamics/medrxiv/tree/main/CST%20publication https://github.com/oxfordBiodynamics/medrxiv/tree/main/CST%20publication